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Abstract objectives Vaccine clinical trials in low-resource settings have unique challenges due to structural
and financial inequities. Specifically, protecting participant and caregiver autonomy to participate in
the research study can be a major challenge, so understanding the setting and contextual factors
which influence the decision process is necessary. This study investigates the experience of caregivers
consenting on behalf of paediatric participants in a malaria vaccine clinical trial where participation
enables access to free, high-quality medical care.
methods We interviewed a total of 78 caregivers of paediatric participants previously enrolled in a
phase II or III malaria vaccine clinical trial in Uganda, Tanzania and Kenya. Interviews were
qualitative and analysed using a thematic framework analysis focusing on the embodied caregiver in
the political, economic and social reality.
results Caregivers of participants in this study made the decision to enrol their child based on
economic, social and political factors that extended beyond the trial into the community and the
home. The provision of health care was the dominant reason for participation. Respondents reported
how social networks, rumours, hierarchal structures, financial constraints and family dynamics
affected their experience with research.
conclusions The provision of medical care was a powerful motivator for participation. Caregiver
choice was limited by structural constraints and scarce financial resources. The decision to participate
in research extended beyond individual consent and was embedded in community and domestic
hierarchies. Future research should assess other contexts to determine how the choice to participate in
research is affected when free medical care is offered.
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Introduction
Vaccines play a major role in public health and their
development is dependent on clinical trial testing in
human populations. Transnational clinical trials operate
through collaborative partnerships that involve a wide
array of stakeholders and participants from varying
sociocultural backgrounds. Each stakeholder enters into
clinical trial research with varying degrees of inequity
linked to its role in the clinical trial and resource context
[1,2]. This inequity is of particular relevance for vaccine
research operating in low-resource settings due to the dis-
crepancy in resources between the trial centre and the
research site in which it operates, which has implications
for the choice to participate in research [3].
Phase II and phase III vaccine clinical trials establish
the safety of a vaccine and determine its efficacy [4].
These trials involve large groups of participants who are
living in the region where the disease targeted by the vac-
cine is endemic. Due to the operation of phase II and III
trials in human communities, the social structures in the
clinical trial site are highly relevant to the clinical trial
© 2019 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1023
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
Tropical Medicine and International Health doi:10.1111/tmi.13281
volume 24 no 8 pp 1023–1030 august 2019
design. To maximise the effectiveness of vaccines cur-
rently in clinical trial development, research needs to be
sensitive to the social systems within the context in which
they are operating [1,2]. To gain a substantive under-
standing of the social system in the clinical trial site,
communities must be engaged and voices of participants
and their families heard [3,5–8]. This engagement process
provides insight into the decision-making structures
around trial participation, communication needs and the
interests of the community in the trial context.
This study investigates the community context, com-
munication needs and decision-making processes of the
caregivers of participants in a phase II and phase III pae-
diatric malaria vaccine clinical trial. Each of these trials
operated in low-resource settings in multiple African
countries. The phase II vaccine trial involved GMZ2
malaria vaccine and was conducted at five clinical trial
centres in four African countries [9]. The phase III trial
involved RTS,S malaria vaccine and was conducted at
eleven clinical trial centres in seven countries [10]. Oper-
ating across social systems, these transnational clinical
trials provide insight into the impact that vaccine clinical
trials have on the local population while adhering to
standardised clinical trial protocols. Local systems and
cultures influence decision-making in clinical trial
research and mapping the country-specific context sup-
ports successful transnational research for development
[11–13]. This study takes these clinical trials as case stud-
ies to map the country-specific context and shed light on
the caregiver and community experiences in clinical
research in low-resource settings.
The phase III RTS,S clinical trial investigated here has
led to the regulatory registration and the roll-out of the
RTS,S vaccine in a phase IV study, making it the first
licenced malaria vaccine. These phase IV studies will take
place in three different countries, including the Kenyan
research centres investigated here [14]. This makes the
experiential understanding of the research participants,
their caregivers and communities in the context of the
clinical trial centre even more pertinent.
While community engagement has been recognised as
necessary in ethical transnational research, there is no
clear consensus as to its definitive application in different
community contexts [15]. Context may influence the
ways in which benefits and risks are perceived by the par-
ticipants, particularly in settings with large resource
inequities [16,17]. Using knowledge of the health and
social structures to inform community engagement prac-
tice is a critical component of designing research studies
appropriately [18]. Researchers conducting clinical trial
studies in low-resource settings can integrate the findings
of this study to protect participant autonomy through
integrating them into the communication of trial proce-
dures.
Methods
In order to better understand the experiences and deci-
sion-making processes of caregivers during the paediatric
malaria vaccine clinical trial, we conducted a series of in-
depth interviews between March 2017 and March 2018
with caregivers of children who participated in a malaria
clinical trial.
Sample population
Interviews were held across four clinical trial sites in
Uganda (Iganga), Kenya (Siaya and Kombewa) and Tan-
zania (Bagamoyo) with caregivers of participants. We
used purposive sampling to recruit respondents and in
the majority of the cases the mother was the primary
caregiver. Participants were selected based on having had
a child enrolled in a paediatric malaria vaccine clinical
trial. Interviews were conducted until saturation was
reached, were semi-structured and held in the home of
the respondent.
Trial
The RTS,S phase III malaria vaccine trial took place
between March 2009 and January 2014 in seven African
countries (Burkina Faso, Gabon, Ghana, Kenya, Malawi,
Mozambique, United Republic of Tanzania) and spanned
11 clinical trial centres [10]. The GMZ2 phase IIb
malaria vaccine trial took place between April 2010 and
July 2012 in four African countries (Burkina Faso (2),
Ghana (1), Uganda (1), Gabon (1)) and spanned five clin-
ical trial centres [9].
Study design
This was a qualitative study that used in-depth interviews
to capture the perspective of the caregiver who had a
child enrolled in a malaria vaccine clinical trial. The field-
work consisted of a scoping trip to the research sites to
introduce the study, recruit participants and meet with
community leaders. Field visits took place in March 2017
(the scoping visit), and the interviews were conducted
between May 2017 and March 2018 with the help of
local research assistants. The research assistants from
Tanzania were fluent in Swahili (one female and one
male). In Uganda, all three female research assistants
were fluent in Luganda and conversational in the related
Lusoga language of the community investigated. In
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Kenya, all three research assistants (one male and two
female) were fluent in Dholuo. None of the research
assistants lived in the community investigated, all were
fluent in English and had post-secondary education. Inter-
views were semi-structured and had a focused discussion
on the vaccine trial, leaving room to explore concepts as
they emerged, such as community dimensions and domes-
tic relationships in the context of the trial. Interviews
began by asking open questions and were then funnelled
into more specific questions about the respondent’s views
and experiences within the health system, interaction
with researchers, and challenges faced in the community.
The interviews were recorded with the informed consent
of the respondent and conducted in the local language.
They were then transcribed verbatim and translated into
English by the research assistant. The interview guide
was first piloted in each country and then changed and
developed throughout to best explore unanticipated
replies as they emerged.
Ethics
The study protocol, informed consent forms and inter-
view guide were reviewed and approved by the following
bodies: in Tanzania, National Health Research Ethics
Review Committee for the National Institute for Medical
Council (NIMR), Ifakara Health Institute IRB (IHI-IRB),
Tanzania Commission for Science and Technology
(COSTECH); in Uganda, Uganda Council for Science and
Technology (UNCST), the Makerere University School of
Biomedical Sciences Higher Degrees Research and Ethics
Committee (SBS-HDREC); in Kenya: Strathmore Univer-
sity IRB (SU-IRB).
Analysis
The analysis was based on the approach described by
Strauss and Corbin (1998) [19]. First, a detailed line-by-
line microanalysis was conducted to identify categories in
the data, followed by an exploration of the categories,
their properties and the relationships between them. This
was discussed between the first author of this paper and
the local bilingual research team to ensure the accuracy
of the analytical process. Categories were defined into
main themes as illustrated in Figure 1. The themes were
then integrated into a framework to define the scope of
the analysis and are presented in the results.
Results
Of the 78 interviews, 23 were with parents of children
enrolled in the GMZ2 Phase IIb trial in Iganga, Uganda.
The remaining 55 in-depth interviews were with parents
of children enrolled in the RTS,S phase III study across
three sites in Bagamoyo, Tanzania (n = 18), Kombewa,
Kenya (n = 20) and Siaya, Kenya (n = 17). Interviews
lasted around 31 min on average, with the longest being
56 min and the shortest being 19 min. Seven interviews
could not be included in the time calculation due to logis-
tical limitations of the recordings.
The respondents made it explicit that they inhabit mul-
tifaceted realities falling under clinical trial, community
and domestic contexts. Each of these themes is shaped
and embedded in their economic, social and political real-
ity (Table 1).
Trial context
Respondents frequently began by explaining their trial
experiences and defined the role the trial played in their
lives. They did not view the clinical trial as detached
from their lives, instead participation was motivated by
an array of political, social and economic factors unique
to their lives.
The mainstream opinion in this sample of respondents
was a great appreciation that the trial provided free,
high-quality medical care for their child during difficult
economic conditions.
R40: Before the research study, when you visit the
government hospital after tests they were telling you
to go buy medicines and sometimes you do not have





Figure 1 Framework for analysis outlining the interplay between
community, domestic and trial contexts that the respondent inhabits
and the economic, political and social realities of the embodied
respondent. [Colour figure can be viewed at wileyonlinelibrary.com]
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situation changed. I am grateful my child was get-
ting malaria tests and given medicines in a sealed
bottle not the opened ones.
The contrast between the free medical care in the study
and the options available to the parents through govern-
ment hospitals was consistently highlighted by respondents.
R56: We were comfortable because the health work-
ers were approaching us well, they had good man-
ners. At times, you may go to the hospital and they
tell you that you are stupid, but these ones were
good health workers, they could tell you to do
something and you accept because of their
approach.
The trial was also not independent from circulating
rumours within social networks. Where the mainstream
in this sample reported an appreciation for the trial and
the medical benefits, a few outliers noted the impact
rumours had on the way the study was perceived and
pushed back against them.
R34: Someone can spread rumours. We would tell
them to go and see for themselves that there is
nothing negative taking place. My child who is in
the study is healthier than yours who is not but you
keep talking about blood draws. You destroy the
image of the study for nothing.
Community context
The community played an integral role in the uptake,
acceptability and integration of the clinical trial into the
local setting. Caregiver decision-making was intimately
tied to their relationship with others in their local com-
munity.
R46: Before joining, I used to see my friends going
and I guessed it would be a good project. When I
joined, I was assured, yes, it was a good project
based on their procedures and services given.
A number of participants reported that the benefits of
the trial should be available to everyone. Placing an
emphasis on the need for the high standard of health care
to be extended towards other members in the commu-
nity.
R32: Your neighbour ought to enjoy what you
enjoy. The fruits you enjoy, he ought to enjoy.
Respondents often reported from the perspective of the
community and how the trial improved conditions for
the children of their community as a whole, despite a
lack of financial resources.
R35: The people were enrolled praised the study.
Most of them are the people who come from around
who earn a little money. Sometimes when the child
falls sick it becomes difficult especially for us who
are farmers. They would give the children effective
drugs. So, the people around consider it good.
The local political leader has a significant influence on
the trial. When the local leader is trusted by the commu-
nity members and this individual approves of the trial,
then the study participants will be much more comfort-
able.
R64: Our chairman as you have seen him, he is
good. Whenever the study people would leave, he
could explain to us what was going on, so that is
how you could pick to participate. These ones who
came straight to the chairman we knew that they
are people of light, because we knew that someone
who has not come through the chairman is the one
you can doubt but someone who has come through
the chairman, there is no need to question.
Table 1 Respondents reported their experience of the trial, com-
munity and domestic context. The dominant themes that arose
during the interviews are displayed
Setting Dominant themes
Trial context • Social networks reported on high-quality
care
• Trial centre vs. government facility medical
care
• Social skills of trial doctors




• Community valued health care
• Reassured by friends about participation
• Health benefits should be for the whole
community
• Trial improved conditions in the
community
• Local leadership influences community
acceptance
• Outlier: Rumours impacted social life
Domestic
context
• Individual context leads to trial enrolment
• Valued health care and improved condition
of child
• Fathers influenced enrolment, consent and
withdrawal
• Explicit reality of sick child in the home
• Outlier: Trial interfered with domestic
harmony
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Where the mainstream in this sample reported satisfac-
tion with the clinical trial, some outliers also reported
cases where community members challenged the clinical
trial and those enrolling their children.
R65: Because at first, the people were asking, why
do you need our children? Which kind of check-up
are you doing? What are you checking? As you
know the village life we are in.
Domestic context
The caregivers of participants in the malaria vaccine clini-
cal trial repeatedly spoke about the role that the trial
played in their lives at home, in particular how the fam-
ily’s access to medication influenced their participation.
R14:My child she was very sick and when I went with
her to the hospital I found the government sector had
no drugs and the study did have drugs. So, I went and
found a sister and she asked me if I could agree to join
the study, ‘if you agree to join then I will take you so
that your child can be helped and if you refuse, you
can go to other district hospital but even there are no
drugs.’ So, I sat with her and asked her and she had
already told me that the study is very good. I asked her
if they can help me and she said yes, only if I agree to
join, and I said yes I have agreed to join and for sure
they treated my child.
Facing financial challenges within the domestic settings
and then having the clinical trial provide free and high-
quality care for the sick children was positive according
to caregivers.
R66: I benefitted because my child is still alive.
R35: My child would be given medication even
when I did not have cash. They would also give me
fare back home. It was good. Anytime I would take
the child to the hospital, they would treat him.
Fathers played a significant role in participation and
many respondents who were mothers elucidated the role
the father had in motivation and consent to join, or with-
drawal from the study.
R17:Others also took it seriously that those people are
removing a lot of blood from the children. So, they did
not agree, and other people, including the fathers of the
children never agreedwhich is why they did not join.
Caregivers also explained what it means for them to
have a sick child within the home, particularly how it
could also lead to problems within the relationships. For
the majority of participants, this was improved when the
children could participate in the study.
R56: You need to eat yet the child is sick. You eat
late because food is prepared late, you quarrel and
can even fight. Such things happen and there is no
love in the family because every time you are con-
centrating on the child. You may find that even
some men get other women, complaining that they
are fed up of the other one because her children are
sickly.
While the mainstream opinion in this qualitative sam-
ple expressed appreciation of the trial and the way in
which it benefited the families, in some exceptional cases
participation in the trial could lead to problems in the
spousal relationship.
R78: They were removing a lot of blood. Maybe
they just needed a lot. I was afraid that he will col-
lapse and his father will beat me up. I was afraid
but there were some women that we went with who
encouraged me to go.
Discussion
The findings of our qualitative in-depth interviews with
caregiver of participants enrolled in a paediatric malaria
vaccine clinical trial provide insight into the values that
caregivers hold, what motivates their participation, and
their experience in the clinical trial. The primary motiva-
tion for participation drew from each theme (trial con-
text, community context, domestic context) and is
intricately connected to the political, social and economic
reality that a caregiver occupies at a given time. Below,
we move through these themes and discuss the role local
values and beliefs play in research participation.
What is most striking about our results is the domi-
nance of free medical care as being the prevailing motiva-
tor for participation. Limited capacity of local medical
services has been raised as a challenge in transnational
research when the medical services in the clinical trial sig-
nificantly surpass local services [20,21]. It is cross-cutting
across all themes analysed in our study and is repeatedly
emphasised by caregivers of participants enrolled in the
clinical trial as being the most valued and positive com-
ponent of the research trial. This finding illustrates the
interplay between the local structural limitations and trial
enrolment, having significant implications for individual
decision-making processes concerning the trial [22,23].
Having a powerful motivating factor, such as the provi-
sion of care in this context, prevalent across all themes, is
indicative of local structural constraints. The provision of
© 2019 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 1027
Tropical Medicine and International Health volume 24 no 8 pp 1023–1030 august 2019
M. van den Berg et al. Trials in low-resource settings: caregivers’ perspectives
care to participants in clinical trial research is presented
as ‘benefit-sharing’ where the clinical trial aims to give
back to participants. This ‘benefit-sharing’ with individ-
ual participants in a setting with ill-functioning institu-
tional health care may impede choice with regards to
enrolment [24]. Failing to balance the provision of care
with concise communication around trial proceedings to
the caregiver can lead to an ‘empty choice’ where struc-
tural factors around health care eliminate an autonomous
decision [25,26]. A caregiver of a participant will be lim-
ited in his or her autonomy when faced with the decision
to enrol when it is the only means to ensure their child’s
health. This is relevant for both informed consent, but
also risk vs. benefit communication in transnational clini-
cal trials [20,26,27].
Beyond the individual, the provision of accessible medi-
cal care was also highlighted as the trial component most
highly valued by the community. Health care was framed
as a community value by respondents. The political lead-
ership which influenced community acceptance of the
research suggests a locus of decision-making that is com-
munal. The leadership decided its position on the
research study and then passed this approval down into
the community, driven by the desire to promote the
health of the children. The provision of health care
within the community context in combination with the
structural constraints impacts decision-making structures
in clinical trials and provides challenges for the consent
process [28]. Communal decision-making extends beyond
traditional liberal political philosophical notions of
autonomy and informed consent, this contextual reality
was described by one caregiver as ‘the village life we are
in’. The respondents are embedded in communal lives
where other members of the community would suggest
their child was going to be killed or face the consequence
of a stigmatised condition if they enrolled in the malaria
vaccine clinical trial. Failing to recognise the contingency
of community and individuality and to overlook the his-
torical experiences that contributed to the generation of
these beliefs can derail research studies [29]. Our results,
in combination with the contingent notion of community
in informed consent processes, place an emphasis on the
need to clearly communicate risks and benefits to the trial
community so that they are not overshadowed by the
benefit associated with healthcare provision.
The final analysis of the domestic context also brought
the value of healthcare provision to the forefront as the
dominating motivator for trial participation. Having a
sick child in the home leads to difficulties for others shar-
ing that same domestic setting, whereas having access to
health care to treat the sick child leads to greater domes-
tic harmony. Respondents reported that enrolling in the
research trial often occurred as a result of the difficulty in
accessing medical care and trial enrolment has been
reported to be lower in areas with better medical services
[30]. This illustrates the power that the provision of med-
ical care has when it is embedded in a low-resource con-
text, distorting a balanced risk and benefit analysis or
leading to the negation of the risks all together.
How parents weigh the risks and benefits of participa-
tion differed and was related to the structural constraints
around healthcare access for the child [25]. Health care
provided by the clinical trial was highly valued by both
parents and improved the condition of the child. This
trickled down into having effects on the relationship the
mother had with the father as well as the overall ‘joy’ in
the home. Having a sick child in the home can burden
the relationship and make parents more likely to partici-
pate in research than when their child is healthy [30].
Individuals living in contexts with few medical services
will see medical provision as a much larger benefit to
their family than those in contexts with a strong local
health system, calling for a tailored communication
approach appropriate for each setting.
The absence of risk in the interviews conducted was also
of note. Sceptical beliefs or concerns were often framed as
‘rumours’ by respondents and those believing themwere
referred to as a distant third party. Respondents repeatedly
emphasised the gratitude they experienced from trial enrol-
ment and the accompanying care. Concerns around poten-
tial adverse events outlined in the informed consent
documents associated with vaccination did not come up as
a significant concern during the interviews.While therapeu-
tic misconception was also evident in some interviews, the
offer of medical care overshadowed it in its ability to influ-
ence the caregiver’s risk perception.
Conclusion
Designing vaccine clinical trials in low-resource settings
such that the communication of risk and benefits is done
in a way that is comprehended by participants and their
communities is a challenging task. Ethical design of
research requires the communication of trial proceedings
not to be overshadowed by the provision of free care in
resource-limited settings. To address this in future trials
and taking the first step towards more ethical communi-
cation means placing the community at the forefront of
research design [31–33]. Putting the community central
to the research means to understand the values present in
the settings where the research is taking place and how
these are situated relative to the individual and their deci-
sion-making processes. This can be achieved through
stronger engagement with local stakeholders and health
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systems, including strengthening the government health
system [34]. The second step is to design clinical trials in
collaborative partnership with local leadership to foster
local capacity building and ultimately strengthen local
health capacities [35]. Being responsive to community
needs and integrating values that influence participation
in research alongside local leadership can provide a more
balanced conception of the risks and benefits. The active
involvement of both community and local leadership can
support the disentanglement of comprehension barriers
while still allowing for ‘benefit-sharing’. An iterative pro-
cess executed by the clinical trial team that engages the
community and works closely with local leadership will
foster research communication and thereby participant
choice.
Understanding and addressing the local context will
reduce inequalities inherent in transnational clinical trials in
low-resource settings [36]. The utilisation of this understand-
ing and its translation into researchwill support the commu-
nication of research appropriate for the local setting [37,38].
This involves integrating the social, political and economic
components into clinical trial design and paving the way
towardsmore equitable research practices and infrastructure
that enables a real choice for study enrolment.
Limitations of this study include the sampling strategy,
which recruited caregivers who enrolled their child and
therefore would have been more likely to have a reduced
risk perception due to the provision of care than care-
givers who were approached and refused to enrol their
child in the clinical trial. Future work investigating the
perception of caregivers in the community who refused to
enrol their child could shed further light on this topic.
We also did not interview and male caregivers, which is
indicative of the traditional caregiving roles where the
mother or grandmother has the primary responsibility for
the child’s health.
Through mapping how contextual realities interplay
with the decision-making process of caregivers of paedi-
atric clinical trial participants, this study can strengthen
clinical trials in low-resource settings. Our work shows
that individual consent in clinical trials is intricately
linked with community consent and family dynamics.
Based on this, future research needs to investigate how
this interplay varies across contexts and the role free
medical care plays in consent in these settings.
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